Pure Red-cell Aplasia Clinical Trial
Official title:
Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
The purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin (EPO) antibody positive pure red cell aplasia (PRCA) in participants with chronic kidney disease who have been recently treated with epoetin alfa (EPREX).
Status | Completed |
Enrollment | 124 |
Est. completion date | March 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - History of anemia due to chronic kidney disease - Pure red cell aplasia (PRCA) associated with erythropoietin-alpha (EPO) treatment - Treatment with EPO for a minimum of 2 months occurring within more or less 3 months of the reference date (date of loss of efficacy [drop in hemoglobin of greater than 2 g/dL/month] was first observed) Exclusion criteria - History of and information related to past exposure to EPO not available - History of PRCA or anti-EPO antibody positive status before or after the reference date |
Observational Model: Case Control, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Brazil, France, Norway, South Africa, Sweden, Thailand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study medication-related risk factors: Number of participants who received Human Serum Albumin (HSA) containing drug | The reference date is the day on which Loss of Efficacy (LOE) was first suspected, where LOE is the date that a drop in hemoglobin of greater than 2 g/dL/month was first seen. | 1 year prior to the reference date | No |
Primary | Study medication-related risk factors: Number of participants who received HSA-free drug | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants who received epoetin alfa intravenously | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants who received epoetin alfa subcutaneously | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants who self-administered epoetin alfa | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants who administered epoetin alfa in hospital or in clinic | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants with the duration of epoetin alfa treatment | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants with the duration of other recombinant human erythropoietins (r-HuEPOs) treatment | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants with exposure to epoetin alfa | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants with exposure to other r-HuEPOs | 1 year prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants with frequency of epoetin alfa dosing | 6 months prior to the reference date | No | |
Primary | Study medication administration-related risk factors: Number of participants with frequency of other r-HuEPOs dosing | 6 months prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants according to age | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants according to sex | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants according to race | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants according to underlying diagnosis of chronic kidney disease | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants according to type of renal replacement therapy (if any at the time of the reference date) | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of malnutrition | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of autoimmune disease or positive results of autoimmune testing | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of immune dysregulation | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with uncontrolled hyperparathyroidism | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with uncontrolled hypothyroidism | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of malignancy | 5 years prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of viral infection | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of vaccination | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with immunosuppressive/immunomodulatory therapy | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with history of frequent transfusions | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with treatment with other subcutaneous medications | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants with treatment with other recombinant human proteins | 1 year prior to the reference date | No | |
Primary | Participant-related risk factors: Number of participants who received other concomitant therapy | 1 year prior to the reference date | No | |
Secondary | Human leukocyte antigen (HLA) typing | The optional pharmacogenomic (use of genetic information to predict whether the study medication will help make a patient well or ill) part of the study will test for polymorphisms and haploid types of the erythropoietin gene. HLA typing will be recorded for the control participants who will sign the pharmacogenomics part of the study. | 1 year prior to the reference date | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00391287 -
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure
|
Phase 4 | |
Completed |
NCT00004378 -
Stem Cell Transplantation (SCT) for Genetic Diseases
|
N/A | |
Completed |
NCT00211042 -
A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment
|
Phase 4 |